Global SPECT and PET Diagnosis Radiopharmaceuticals Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
Description
According to our (Global Info Research) latest study, the global SPECT and PET Diagnosis Radiopharmaceuticals market size was valued at US$ 5901 million in 2025 and is forecast to a readjusted size of US$ 9269 million by 2032 with a CAGR of 6.7% during review period.
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
This report is a detailed and comprehensive analysis for global SPECT and PET Diagnosis Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for SPECT and PET Diagnosis Radiopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global SPECT and PET Diagnosis Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Eli Lilly, China Isotope & Radiation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
SPECT and PET Diagnosis Radiopharmaceuticals market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Technetium 99
Fluorine 18
Other
Market segment by Imaging Modality
PET Imaging
SPECT Imaging
Market segment by End User
Hospitals
Imaging Centers
Other
Market segment by Application
Oncology
Cardiology
Other
Major players covered
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Eli Lilly
China Isotope & Radiation
Dongcheng
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe SPECT and PET Diagnosis Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of SPECT and PET Diagnosis Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of SPECT and PET Diagnosis Radiopharmaceuticals from 2021 to 2026.
Chapter 3, the SPECT and PET Diagnosis Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the SPECT and PET Diagnosis Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and SPECT and PET Diagnosis Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of SPECT and PET Diagnosis Radiopharmaceuticals.
Chapter 14 and 15, to describe SPECT and PET Diagnosis Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
SPECT and PET diagnosis radiopharmaceuticals refer to nuclear medicine diagnostic agents used in Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These agents are typically formed by combining radioactive isotopes with biologically active molecules such as small compounds, peptides, or antibodies through chemical or biological conjugation. After administration, the radiopharmaceutical participates in specific physiological or biochemical processes in the body and emits detectable radiation signals that can be captured by imaging systems, enabling visualization of organ function, metabolic activity, and molecular-level biological changes. SPECT and PET radiopharmaceuticals are widely used in oncology diagnostics, cardiovascular evaluation, neurological disease detection, and the localization of infection or inflammation. They play a fundamental role in molecular imaging and precision medicine. With the development of targeted molecular probes and new radionuclides, these agents are evolving from traditional functional imaging toward early disease detection and molecular mechanism diagnostics, becoming an essential component of modern medical imaging systems.In 2025, global SPECT and PET diagnosis radiopharmaceutical production reached approximately X156.28 million Units and price is about 36.7USD/Unit.The average gross profit margin of this product is 65%.
With the rapid advancement of precision medicine and molecular imaging technologies, SPECT and PET diagnostic radiopharmaceuticals are becoming increasingly important in modern healthcare systems. The growing need for early diagnosis of cancer, neurological disorders, and cardiovascular diseases has significantly expanded the role of molecular imaging in clinical practice. Continuous development of targeted molecular probes and new radionuclides enables radiopharmaceuticals to more accurately reflect metabolic processes and molecular activities in the body, improving diagnostic sensitivity and specificity. In addition, the expansion of nuclear medicine centers, upgrades in medical imaging infrastructure, and the integration of diagnostic and therapeutic approaches are further accelerating the clinical adoption of SPECT and PET diagnostic agents.
Despite their high clinical value and technological sophistication, SPECT and PET diagnostic radiopharmaceuticals face several industry challenges. The development, production, and transportation of radioactive drugs require strict regulatory compliance related to nuclear safety and pharmaceutical quality control, which imposes high operational standards on manufacturers. Some critical radioisotopes have short half-lives, requiring reliable isotope supply systems and highly efficient logistics networks, which adds complexity to the supply chain. Additionally, the shortage of specialized nuclear medicine professionals and the uneven technical capabilities of medical institutions may affect the broader adoption and commercialization of these diagnostic agents.
In downstream medical applications, the role of SPECT and PET radiopharmaceuticals is gradually shifting from traditional organ function imaging toward molecular-level disease detection. PET imaging has become increasingly important for tumor staging, therapy response evaluation, and recurrence monitoring. Meanwhile, demand is growing in areas such as neurodegenerative diseases, inflammatory disorders, and immune-related conditions. With the development of personalized medicine, targeted diagnostic probes designed for specific biological markers are expanding, creating closer synergy between diagnostic imaging and targeted therapy. In the future, theranostic radiopharmaceuticals and companion diagnostics are expected to become key growth areas.
The upstream supply chain of SPECT and PET diagnostic radiopharmaceuticals mainly includes radioactive isotopes, chemical precursor molecules, and radiolabeling reagents. Commonly used radionuclides include technetium isotopes, fluorine isotopes, and iodine isotopes, which are typically produced through nuclear reactors or medical cyclotrons. Chemical precursor molecules serve as carriers that bind to radioactive isotopes to form specific molecular probes, and their structural design directly influences targeting capability and imaging performance. In addition, stable radiolabeling technologies and high-purity reagents are essential for ensuring the safety and imaging quality of these drugs. With the continuous evolution of nuclear medicine technologies, upstream materials are moving toward higher purity, better stability, and enhanced targeting efficiency.
This report is a detailed and comprehensive analysis for global SPECT and PET Diagnosis Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global SPECT and PET Diagnosis Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for SPECT and PET Diagnosis Radiopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global SPECT and PET Diagnosis Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Eli Lilly, China Isotope & Radiation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
SPECT and PET Diagnosis Radiopharmaceuticals market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Technetium 99
Fluorine 18
Other
Market segment by Imaging Modality
PET Imaging
SPECT Imaging
Market segment by End User
Hospitals
Imaging Centers
Other
Market segment by Application
Oncology
Cardiology
Other
Major players covered
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Eli Lilly
China Isotope & Radiation
Dongcheng
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe SPECT and PET Diagnosis Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of SPECT and PET Diagnosis Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of SPECT and PET Diagnosis Radiopharmaceuticals from 2021 to 2026.
Chapter 3, the SPECT and PET Diagnosis Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the SPECT and PET Diagnosis Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and SPECT and PET Diagnosis Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of SPECT and PET Diagnosis Radiopharmaceuticals.
Chapter 14 and 15, to describe SPECT and PET Diagnosis Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Table of Contents
122 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: SPECT and PET Diagnosis Radiopharmaceuticals by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
